Clinical Trial Update: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating dabrafenib plus trametinib in previously treated metastatic, radioactive iodine-refractory BRAF V600E–positive differentiated thyroid c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Differentiated Thyroid Cancer (DTC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING